NCT02542254View on ClinicalTrials.gov

The Effects of RPL554 on Top of Standard COPD Reliever Medications

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Salbutamol

200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)

DRUG

Ipratropium

40 micrograms ipratropium administered using a pMDI

DRUG

RPL554

6 mg RPL554 administered using a nebuliser

DRUG

Salbutamol matched placebo

Placebo pMDI

DRUG

Ipratropium matched placebo

Placebo pMDI

DRUG

RPL554 matched placebo

Nebulised placebo

Trial Locations (1)

Unknown

Medicines Evaluation Unit, Manchester

All Listed Sponsors
lead

Verona Pharma plc

INDUSTRY

NCT02542254 - The Effects of RPL554 on Top of Standard COPD Reliever Medications | Biotech Hunter | Biotech Hunter